387 related articles for article (PubMed ID: 21896721)
1. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
2. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.
Bitoun E; Oliver PL; Davies KE
Hum Mol Genet; 2007 Jan; 16(1):92-106. PubMed ID: 17135274
[TBL] [Abstract][Full Text] [Related]
3. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
4. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
5. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
6. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
7. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.
Benedikt A; Baltruschat S; Scholz B; Bursen A; Arrey TN; Meyer B; Varagnolo L; Müller AM; Karas M; Dingermann T; Marschalek R
Leukemia; 2011 Jan; 25(1):135-44. PubMed ID: 21030982
[TBL] [Abstract][Full Text] [Related]
8. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
9. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
Muntean AG; Tan J; Sitwala K; Huang Y; Bronstein J; Connelly JA; Basrur V; Elenitoba-Johnson KS; Hess JL
Cancer Cell; 2010 Jun; 17(6):609-21. PubMed ID: 20541477
[TBL] [Abstract][Full Text] [Related]
10. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
11. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
12. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP.
Sobhian B; Laguette N; Yatim A; Nakamura M; Levy Y; Kiernan R; Benkirane M
Mol Cell; 2010 May; 38(3):439-51. PubMed ID: 20471949
[TBL] [Abstract][Full Text] [Related]
14. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
15. MLL fusion partners AF4 and AF9 interact at subnuclear foci.
Erfurth F; Hemenway CS; de Erkenez AC; Domer PH
Leukemia; 2004 Jan; 18(1):92-102. PubMed ID: 14603337
[TBL] [Abstract][Full Text] [Related]
16. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
17. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.
Yokoyama A; Lin M; Naresh A; Kitabayashi I; Cleary ML
Cancer Cell; 2010 Feb; 17(2):198-212. PubMed ID: 20153263
[TBL] [Abstract][Full Text] [Related]
18. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
19. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
20. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Mueller D; Bach C; Zeisig D; Garcia-Cuellar MP; Monroe S; Sreekumar A; Zhou R; Nesvizhskii A; Chinnaiyan A; Hess JL; Slany RK
Blood; 2007 Dec; 110(13):4445-54. PubMed ID: 17855633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]